2018
Trends in Heart failure Hospitalization, In-hospital Mortality, Length of Stay and Disposition, Among ESRD patients on Dialysis (2001-2014)
Inampudi C, Akintoye E, Alvarez P, Bhama J, Briasoulis A. Trends in Heart failure Hospitalization, In-hospital Mortality, Length of Stay and Disposition, Among ESRD patients on Dialysis (2001-2014). Journal Of Cardiac Failure 2018, 24: s104. DOI: 10.1016/j.cardfail.2018.07.393.Peer-Reviewed Original ResearchLength of stayEnd-stage renal diseasePrimary HF admissionsHospital mortalityESRD patientsHeart failureHF admissionsEnd-stage renal disease patientsStage renal disease patientsAnnual national ratesPrimary HF hospitalizationsHeart failure hospitalizationRenal disease patientsBackground Cardiovascular diseaseNational Inpatient SampleRate of admissionAnnual percentage changeHF hospitalizationFailure hospitalizationHome dischargeRenal diseaseDisease patientsInpatient SampleCardiovascular diseaseCommon cause
2017
Hungry bone syndrome two weeks after starting cinacalcet: a call for caution
Koubar SH, Qannus AA, Medawar W, Abu-Alfa AK. Hungry bone syndrome two weeks after starting cinacalcet: a call for caution. CEN Case Reports 2017, 7: 21-23. PMID: 29124559, PMCID: PMC5886916, DOI: 10.1007/s13730-017-0284-z.Peer-Reviewed Case Reports and Technical NotesEnd-stage renal disease patientsStage renal disease patientsHungry bone syndromeComplications of treatmentRenal disease patientsYear old manPharmacological parathyroidectomySecondary hyperparathyroidismBone syndromeHospital admissionProlonged hypocalcemiaSerum calciumDisease patientsElemental calciumActivation therapyNormal rangeOlder menCinacalcetHigh dosesSafe alternativeTwo weeksParathyroidectomyWeeksHypocalcemiaDrugs
1998
Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up.
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clinical Nephrology 1998, 50: 101-7. PMID: 9725781.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionIntradialytic hypotensionMidodrine therapyHD sessionSafe therapyEnd-stage renal disease patientsStage renal disease patientsAlpha-1 adrenergic agonistMean ultrafiltration volumeSignificant causative roleRenal disease patientsTreatment-related factorsPatient-specific factorsMost therapeutic interventionsKt/VHypotensive symptomsBlood pressureHemodialysis patientsHD patientsDisease patientsSubjective improvementAdverse reactionsFrustrating complicationMean albuminSafe treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply